Business Wire·Jul 23, 2026, 8:01 AM ET

Lantern Pharma Receives USPTO Notice of Allowance for Patent Covering Biomarker-Guided Treatment with LP-184 (Zirdafulven) in Multiple Solid Tumor Cancers

US Patent and Trademark Office issued Notice of Allowance for U.S. Patent Application No. 17/230,821 covering methods to treat solid tumors using LP-184 (zirdafulven) & a three-gene biomarker signature.
The allowed patent claims define the use of elevated expression of PTGR1, PTPN14, & ASPH genes to select patients with ovarian, primary liver, kidney, or thyroid cancer for LP-184 treatment.
A completed 63-patient Phase 1a trial in recurrent or refractory advanced solid tumors showed a 45% disease control rate among patients treated at or above the effective therapeutic dose.
Lantern Pharma plans to evaluate LP-184 in multiple precision oncology Phase 1b/2 clinical trials targeting advanced aggressive & rare cancers during 2026.
LP-184 functions as a prodrug selectively activated inside cancer cells by the enzyme PTGR1 to induce irreparable DNA damage in tumors with deficient DNA damage repair pathways.
Lantern's proprietary RADR® artificial intelligence platform identified PTGR1 overexpression & low expression of DNA damage repair genes as strong predictors of LP-184 sensitivity.
LP-184 holds FDA Fast Track Designation for TNBC & GBM, & Orphan Drug Designation for malignant gliomas, pancreatic cancer, & ATRT.
Lantern intends to expand its patent portfolio with additional filings covering further indications & biomarker-guided applications of LP-184.